MedTrace Logo

Factor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins After Scheduled Hip Replacement (ONYX-2)

NCT00353678 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1141

Last updated 2013-03-21

No results posted yet for this study

Summary

The purpose of this study is to find the best possible (optimal) dose (effect versus adverse events) of YM150 to prevent the risk of blood clot formation after scheduled hip replacement surgery.

Conditions

  • Thromboembolism

Interventions

DRUG

YM150

Sponsors & Collaborators

  • Astellas Pharma Europe B.V.

    collaborator INDUSTRY

  • Astellas Pharma Inc

    lead INDUSTRY

Principal Investigators

  • Astellas Pharma Europe B.V., Medical Clinical Development · Department of Orthopedics, Surgical Sciences, Gothenburg University Sahlgrenska/ÖSTRA University Hospital, Goteborg, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2007-08-31
Completion
2007-08-31

Countries

  • Austria
  • Bosnia and Herzegovina
  • Czechia
  • Denmark
  • Finland
  • Germany
  • Greece
  • Italy
  • Latvia
  • Lithuania
  • Norway
  • Poland
  • Russia
  • Serbia
  • Slovakia
  • Spain
  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00353678 on ClinicalTrials.gov